Neuroscientific Biopharmaceuticals Ltd.ASX: NSB

Appointment of Executive Director & FDA Pre-Ind Meeting

· Issued by Neuroscientific Biopharmaceuticals Ltd.

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Neuroscientific Biopharmaceuticals Ltd. has announced the appointment of Dr. Tony Keating as Executive Director following the resignation of Dougal Thring as chief operating officer. The company has also filed a Pre-Investigation New Drug Application meeting request with the FDA for EmtinB, aimed at treating advanced glaucoma in adults. This meeting is expected to clarify the regulatory requirements for progressing towards an investigational new drug application.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Neuroscientific Biopharmaceuticals Ltd. on 6ix

Earlier from Neuroscientific Biopharmaceuticals

Later from Neuroscientific Biopharmaceuticals

All Neuroscientific Biopharmaceuticals news releases